Ferric carboxymaltose

Drug Profile

Ferric carboxymaltose

Alternative Names: Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy®; VIT-45; Z-213

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Vifor
  • Developer Luitpold Pharmaceuticals; Vifor; Zeria
  • Class Antianaemics; Heavy metals; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Chronic heart failure; Restless legs syndrome

Most Recent Events

  • 27 Jan 2017 Luitpold Pharmaceuticals and Duke Clinical Research Institute plan a phase III trial for Chronic heart failure (with iron deficiency and a reduced ejection fraction) in USA (IV) (NCT03037931)
  • 01 Nov 2016 Efficacy data from a phase III trial in Chronic heart failure presented at the 88th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 05 Jul 2016 Luitpold Pharmaceuticals plans a phase II trial for Restless legs syndrome in patients with Iron deficiency anaemia in USA (IV, Infusion) (NCT02826681)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top